Rigel Pharmaceuticals (NASDAQ:RIGL) is set to release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Rigel Pharmaceuticals to post earnings of ($0.14) per share for the quarter.
Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.02. The firm had revenue of $12.62 million during the quarter, compared to analyst estimates of $12.00 million. Rigel Pharmaceuticals had a negative return on equity of 58.94% and a negative net margin of 111.48%. During the same period last year, the company earned ($0.17) earnings per share. On average, analysts expect Rigel Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
RIGL traded up $0.03 during midday trading on Wednesday, reaching $2.33. 27,751 shares of the company’s stock traded hands, compared to its average volume of 837,705. The firm has a fifty day moving average price of $2.39. The company has a market cap of $384.54 million, a PE ratio of -5.31 and a beta of 1.26. The company has a quick ratio of 5.29, a current ratio of 5.33 and a debt-to-equity ratio of 0.26. Rigel Pharmaceuticals has a 52 week low of $1.96 and a 52 week high of $3.65.
In other Rigel Pharmaceuticals news, CFO Dean L. Schorno bought 50,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were bought at an average cost of $2.13 per share, with a total value of $106,500.00. Following the completion of the acquisition, the chief financial officer now owns 46,726 shares of the company’s stock, valued at $99,526.38. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.96% of the stock is currently owned by corporate insiders.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia.
Featured Article: How to use beta for portfolio diversification
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.